387 related articles for article (PubMed ID: 18220769)
21. Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.
Tremblay MR; Lin SX; Poirier D
Steroids; 2001 Nov; 66(11):821-31. PubMed ID: 11576622
[TBL] [Abstract][Full Text] [Related]
22. Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.
Wang X; Gérard C; Thériault JF; Poirier D; Doillon CJ; Lin SX
J Mol Cell Biol; 2015 Dec; 7(6):568-79. PubMed ID: 25966904
[TBL] [Abstract][Full Text] [Related]
23. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
[TBL] [Abstract][Full Text] [Related]
24. Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Chetrite GS; Ebert C; Wright F; Philippe JC; Pasqualini JR
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):51-6. PubMed ID: 10215037
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.
Sancéau JY; Maltais R; Zhou M; Lin SX; Poirier D
J Steroid Biochem Mol Biol; 2024 Sep; 242():106544. PubMed ID: 38754521
[TBL] [Abstract][Full Text] [Related]
28. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
29. Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Lespérance M; Barbeau X; Roy J; Maltais R; Lagüe P; Poirier D
Steroids; 2018 Dec; 140():104-113. PubMed ID: 30273695
[TBL] [Abstract][Full Text] [Related]
30. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Ngueta AD; Roy J; Maltais R; Poirier D
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
[TBL] [Abstract][Full Text] [Related]
31. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
33. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
[TBL] [Abstract][Full Text] [Related]
34. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.
Krazeisen A; Breitling R; Möller G; Adamski J
Mol Cell Endocrinol; 2001 Jan; 171(1-2):151-62. PubMed ID: 11165023
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of 17 beta-hydroxysteroid dehydrogenases.
Poirier D
Curr Med Chem; 2003 Mar; 10(6):453-77. PubMed ID: 12570693
[TBL] [Abstract][Full Text] [Related]
36. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Bellavance E; Luu-The V; Poirier D
J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
[TBL] [Abstract][Full Text] [Related]
37. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.
Poirier D
Expert Opin Ther Pat; 2010 Sep; 20(9):1123-45. PubMed ID: 20645882
[TBL] [Abstract][Full Text] [Related]
38. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
39. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC
Abdelsamie AS; van Koppen CJ; Bey E; Salah M; Börger C; Siebenbürger L; Laschke MW; Menger MD; Frotscher M
Eur J Med Chem; 2017 Feb; 127():944-957. PubMed ID: 27852458
[TBL] [Abstract][Full Text] [Related]
40. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
